StemCell Institute (TSE:7096) EBIT: 円223 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7096 StemCell Institute TSE:7096
69 GF Score
Price 円770.00
GF Value 円1,813.82
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is StemCell Institute EBIT?

StemCell Institute TSE:7096 +0.26% 69 EBIT is 円223 Mil as of Mar. 2026. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.82 (Possible Value Trap). The stock has 6 warning signs investors should review.

StemCell Institute's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円223 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. StemCell Institute's annualized ROC % for the quarter that ended in Mar. 2026 was 1.19%. StemCell Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. StemCell Institute's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.15%.

StemCell Institute  (TSE:7096) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

StemCell Institute's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=144.508 * ( 1 - 42.79% )/( (6795.245 + 7140.786)/ 2 )
=82.6730268/6968.0155
=1.19 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7852.76 - 97.15 - ( 3067.228 - max(0, 4323.473 - 5283.838+3067.228))
=6795.245

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8124.841 - 202.605 - ( 2834.134 - max(0, 4532.174 - 5313.624+2834.134))
=7140.786

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

StemCell Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=166.762/( ( (1161.451 + max(-2044.535, 0)) + (1375.042 + max(-1981.813, 0)) )/ 2 )
=166.762/( ( 1161.451 + 1375.042 )/ 2 )
=166.762/1268.2465
=13.15 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2076.528 + 57.922 + 82.16) - (97.15 + 0 + 4163.995)
=-2044.535

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2337.026 + 54.021 + 88.442999999999) - (202.605 + 0 + 4258.698)
=-1981.813

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

StemCell Institute's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=223.234/5373.578
=4.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCell Institute EBIT Related Terms

StemCell Institute EBIT Historical Data

* Premium members only.

The historical data trend for StemCell Institute's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCell Institute EBIT Chart

StemCell Institute Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only 212.58 297.56 413.76 566.91 223.23

StemCell Institute Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 198.47 258.06 308.85 139.85 83.38

TSE:7096 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, StemCell Institute's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StemCell Institute EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCell Institute's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where StemCell Institute's EV-to-EBIT falls into.


TSE:7096
69GF Score
StemCell Institute TSE:7096
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCell Institute EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円223 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円223 Mil mean?
StemCell Institute (TSE:7096) has a EBIT of 円223 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on StemCell Institute.
Is StemCell Institute's EBIT too high?
StemCell Institute's current EBIT is 円223 Mil. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's EBIT compare to VRTX and REGN?
StemCell Institute's EBIT of 円223 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on StemCell Institute. StemCell Institute's current EBIT is 円223 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.82, compared to a current price of 円770.00 — trading 57.5% below its estimated fair value. The current EBIT is 円223 Mil. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current EBIT is 円223 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is StemCell Institute (TSE:7096) Overvalued in 2026?

Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued. The current stock price of 円770.00 is trading 57.5% below its estimated GF Value™ of 円1,813.82. GuruFocus considers StemCell Institute to be Possible Value Trap.

Key valuation signals for TSE:7096:

  • EBIT: 円223 Mil
  • GF Value™: 円1,813.82 vs. price of 円770.00 (57.5% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

StemCell Institute Business Description

Address 1-21-19 Toranomon, Minato-ku, Tokyo, JPN, 105-0001
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score

Get the complete analysis for TSE:7096

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円770.00
Price
円1,813.82
GF Value